Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04827147 · ClinicalTrials.gov registry record · NA
Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia
A NA study of Homonymous Hemianopia, sponsored by Massachusetts Eye and Ear Infirmary.
- Active
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 8
- Study locations
NCT04827147: Active NA study of Homonymous Hemianopia, sponsored by Massachusetts Eye and Ear Infirmary.
NCT04827147 is a NA study of Homonymous Hemianopia that is active but no longer recruiting, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 64 participants, above the 35-participant average among 3 other Homonymous Hemianopia trials with a reported enrollment target (83% higher). The trial reports 8 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04827147, a NA study of Homonymous Hemianopia, is active but no longer recruiting, sponsored by Massachusetts Eye and Ear Infirmary.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 8
- Study locations
Study Summary
This clinical trial will evaluate the efficacy of two types of high-power prism glasses that provide field of view expansion for patients with homonymous hemianopia (the complete loss of half the field of vision on the same side in both eyes).
Primary Outcome
Improvement in detection rate with prism glasses for hazards approaching from the blind side at a bearing angle of 40 degrees in the VR walking simulator test. Improvement is a binary outcome, defined as blind-side detection rate (number of pedestrians detected as a percentage of the total number of pedestrian events) which is significantly higher (z-test for two proportions) with than without prism glasses at the same visit.
Conditions Studied
Interventions
- DEVICE Multi-Periscopic Prism (MPP) glasses
- DEVICE Fresnel Peripheral Prism (FPP) glasses
Study Locations (8)
Massachusetts
- Schepens Eye Research Institute - Boston
- New England College of Optometry - Boston
- The Eye and Vision Center at MCPHS - Worcester
- UMass Chan Medical School - Worcester
Alabama
- UAB Center for Low Vision Rehabilitation, Callahan Eye Hospital - Birmingham
Colorado
- UCHealth Sue Anschutz-Rodgers Eye Center - Denver
Florida
- Visual Health and Surgical Center - Palm Springs
Illinois
- Illinois College of Optometry - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2022-10-03 |
| Est. Completion | 2026-04-30 |
| Phase | NA |
What the registry record for NCT04827147 still lists
NCT04827147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, above the 35-participant average among 3 other Homonymous Hemianopia trials with a reported enrollment target (83% higher).
The record links to 1 condition, with Homonymous Hemianopia appearing as the primary indexed condition, and to 2 interventions - of which Multi-Periscopic Prism (MPP) glasses is the first listed.
NCT04827147 lists 8 locations in 5 states (Massachusetts, Alabama, Colorado).
Frequently Asked Questions
What is clinical trial NCT04827147 about?
NCT04827147 is a clinical study titled "Clinical Trial of Multi-Periscopic Prism Glasses for Hemianopia". This clinical trial will evaluate the efficacy of two types of high-power prism glasses that provide field of view expansion for patients with homonymous hemianopia (the complete loss of half the field of vision on the same side in both eyes).
What is the current status of trial NCT04827147?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 64 participants. The study started on 2022-10-03. Estimated completion is 2026-04-30.
What conditions does trial NCT04827147 study?
This clinical trial studies the following conditions: Homonymous Hemianopia.
What interventions are being tested in trial NCT04827147?
The interventions under investigation include: Multi-Periscopic Prism (MPP) glasses (DEVICE), Fresnel Peripheral Prism (FPP) glasses (DEVICE).
Who is sponsoring clinical trial NCT04827147?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04827147 being conducted?
This trial has 8 study locations across Alabama, Colorado, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Homonymous Hemianopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI